In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder
NIDA - National Institute on Drug Abuse
About This Grant
Opioid analgesics (e.g. fentanyl, morphine, oxycodone) are widely used to treat and manage moderate to severe acute pain resulting from trauma or surgery as well as some types of chronic pain. It is well established that these drugs exert their influence through activation of the µ-opioid receptor. Unfortunately, opioids are also highly addictive and physical dependence on these drugs can be established after as little as a few days of sustained use. Between 1999 and 2020, >565,000 people died from an opioid involved overdose, and in 2022 nearly 70% of drug overdose deaths (~74K of ~108K) involved synthetic opioids, primarily fentanyl. In addition, according to the National Survey on Drug Use and Health, ~2.7 million people were suffering with opioid use disorder (OUD) in 2020 and the economic impact of the opioid crisis in the US was ~$1.5 trillion. Although treatments such as Methadone (Dolophine), Buprenorphine (Subutex) and Naltrexone (Revia) are available, only 24% of OUD patients received treatment in 2022 and the risk of relapse is high. The danger of long-term opioid use extends beyond the risk of overdose death, as patient experiencing OUD are at increased risk for a wide range of additional negative health consequences. There is a clear, present, and persistent need to develop novel therapies for OUD. Studies demonstrate that antagonism of the 5-HT7 receptor can regulate key dopamine pathways involved in substance use disorder and improve cognitive flexibility and memory. These improvements are especially noted in assays with links to negative states such as psychosis, depression, stress, and withdrawal. We have identified a series of novel, drug-like 5-HT7 antagonists that include a lead compound, PRA078, which produces a statistically significant reduction in a cue-induced reinstatement rat model of cocaine use disorder. In this program, we will determine the impact of our lead compound on rat models of opioid use disorder. This data will support our continued advancement of this compound into pre-clinical IND enabling studies as a treatment for opioid use disorder.
Grant Summary
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder is a NIDA - National Institute on Drug Abuse grant providing up to $355K for university, nonprofit, healthcare org. Applications are due 2027-05-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $355K
2027-05-31
- 1Confirm your organization is eligible for In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder from NIDA - National Institute on Drug Abuse, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDA - National Institute on Drug Abuse before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDA - National Institute on Drug Abuse's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder: Frequently Asked Questions
Who is eligible for the In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder?
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder is offered by NIDA - National Institute on Drug Abuse and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder provide?
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder provides up to $355K per award from NIDA - National Institute on Drug Abuse. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder deadline?
Applications for In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder are due 2027-05-31 (open). Because deadlines can change, verify the date with the funder, NIDA - National Institute on Drug Abuse, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder?
To apply for In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDA - National Institute on Drug Abuse.